Published in Int J Biochem Cell Biol on May 31, 2013
Apolipoprotein E3 Inhibits Rho to Regulate the Mechanosensitive Expression of Cox2. PLoS One (2015) 0.79
Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl (2017) 0.75
Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev (2004) 16.52
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med (1990) 3.17
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation (2000) 3.05
Mechanisms of vascular smooth muscle cell migration. Circ Res (2007) 2.57
Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation (1986) 2.06
Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation. Circ Res (2006) 1.79
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol (2003) 1.66
Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation (2000) 1.65
Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res (2002) 1.59
Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol (2012) 1.43
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation (2004) 1.43
HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation (1989) 1.43
Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications. J Vasc Surg (2009) 1.35
Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.32
Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res (2002) 1.32
Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis (1989) 1.29
Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg (2002) 1.17
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Expression profiling identifies smooth muscle cell diversity within human intima and plaque fibrous cap: loss of RGS5 distinguishes the cap. Arterioscler Thromb Vasc Biol (2005) 1.10
Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation (1988) 1.09
Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2000) 1.07
Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol (1991) 1.07
Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry (1991) 1.06
External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nat Med (1998) 1.06
Expansive remodeling in venous bypass grafts: novel implications for vein graft disease. Atherosclerosis (2007) 1.02
Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells. Atherosclerosis (2006) 0.98
The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis (1993) 0.96
Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells. Hypertension (2002) 0.95
Statins and myocardial remodelling: cell and molecular pathways. Expert Rev Mol Med (2011) 0.92
Differential gene expression in vascular smooth muscle cells in primary atherosclerosis and in stent stenosis in humans. Arterioscler Thromb Vasc Biol (2002) 0.92
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91
CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation (2000) 0.91
Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits. Circulation (2001) 0.90
The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem (2003) 0.87
The mechanism of angiotensin II-induced extracellular signal-regulated kinase-1/2 activation is independent of angiotensin AT(1A) receptor internalisation. Cell Signal (2001) 0.87
Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg (2003) 0.87
Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood (1997) 0.86
Lipoprotein (a) and carotid atherosclerosis in young patients with stroke. Stroke (2011) 0.85
Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res (2000) 0.83
Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3. Biochem J (2009) 0.82
Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem (2004) 0.82
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J Surg Res (2005) 0.82
Lipoprotein(a): Cellular Effects and Molecular Mechanisms. Cholesterol (2012) 0.82
Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol (1993) 0.81
The assembly of lipoprotein Lp(a). Eur J Clin Invest (1996) 0.79
Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Ann Pharmacother (2007) 0.78
Effects of wild-type (Trp72) and mutant (Arg72) apolipoprotein(a) kringle IV-10 on the proliferation of human arterial smooth muscle cells. Chin Med J (Engl) (2003) 0.77
Apoptosis, cell proliferation and modulation of cyclin-dependent kinase inhibitor p21(cip1) in vascular remodelling during vein arterialization in the rat. Int J Exp Pathol (2009) 0.77
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet (2011) 7.50
Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet (2009) 5.84
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther (2009) 4.21
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. Nat Genet (2010) 3.66
Quantification of homozygosity in consanguineous individuals with autosomal recessive disease. Am J Hum Genet (2006) 3.52
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
A genomewide linkage study of 1,933 families affected by premature coronary artery disease: The British Heart Foundation (BHF) Family Heart Study. Am J Hum Genet (2005) 3.20
A European training system in cardiothoracic surgery: is it time? Eur J Cardiothorac Surg (2012) 2.89
Assessment of non-ST-segment elevation acute coronary syndromes with cardiac magnetic resonance imaging. J Am Coll Cardiol (2004) 2.88
Autosomal recessive primary microcephaly (MCPH): a review of clinical, molecular, and evolutionary findings. Am J Hum Genet (2005) 2.86
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
A sphingosine-1-phosphate-activated calcium channel controlling vascular smooth muscle cell motility. Circ Res (2006) 2.12
The predicted coiled-coil domain of myosin 10 forms a novel elongated domain that lengthens the head. J Biol Chem (2005) 2.11
TRPC channel activation by extracellular thioredoxin. Nature (2008) 1.97
Differential trafficking of Kif5c on tyrosinated and detyrosinated microtubules in live cells. J Cell Sci (2008) 1.94
Reperfusion haemorrhage as determined by cardiovascular MRI is a predictor of adverse left ventricular remodelling and markers of late arrhythmic risk. Heart (2010) 1.89
What primary microcephaly can tell us about brain growth. Trends Mol Med (2006) 1.76
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation (2007) 1.69
Cardiac surgical theatre traffic: time for traffic calming measures? Interact Cardiovasc Thorac Surg (2010) 1.59
Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell (2005) 1.58
Nesprin-2 interacts with meckelin and mediates ciliogenesis via remodelling of the actin cytoskeleton. J Cell Sci (2009) 1.58
Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers. Cardiovasc Res (2010) 1.57
The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail (2010) 1.57
The spatial and temporal dynamics of pleckstrin homology domain binding at the plasma membrane measured by imaging single molecules in live mouse myoblasts. J Biol Chem (2004) 1.57
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Translocon closure to Ca2+ leak in proliferating vascular smooth muscle cells. Am J Physiol Heart Circ Physiol (2009) 1.52
Coronary artery disease: myocardial perfusion MR imaging with sensitivity encoding versus conventional angiography. Radiology (2005) 1.48
Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension. Hypertension (2004) 1.48
Surgical training in the 48-h week: a novel simulation and educational tool. From amateur golfer to professional pilot. Eur J Cardiothorac Surg (2009) 1.47
Orai1 and CRAC channel dependence of VEGF-activated Ca2+ entry and endothelial tube formation. Circ Res (2011) 1.47
Interactions, functions, and independence of plasma membrane STIM1 and TRPC1 in vascular smooth muscle cells. Circ Res (2008) 1.45
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail (2003) 1.41
Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer (2003) 1.33
Mesenchymal stem cell migration is regulated by fibronectin through α5β1-integrin-mediated activation of PDGFR-β and potentiation of growth factor signals. J Cell Sci (2011) 1.33
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.33
Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res (2008) 1.29
A FERM domain autoregulates Drosophila myosin 7a activity. Proc Natl Acad Sci U S A (2009) 1.29
The SAH domain extends the functional length of the myosin lever. Proc Natl Acad Sci U S A (2009) 1.29
Human ASPM participates in spindle organisation, spindle orientation and cytokinesis. BMC Cell Biol (2010) 1.29
Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction. Circ Res (2010) 1.28
Clinical evaluation of magnetic resonance imaging in coronary heart disease: the CE-MARC study. Trials (2009) 1.26
Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J (2005) 1.25
Robotic multiwell planar patch-clamp for native and primary mammalian cells. Nat Protoc (2009) 1.25
Jouberin localizes to collecting ducts and interacts with nephrocystin-1. Kidney Int (2008) 1.24
Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem (2004) 1.21
Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res (2007) 1.20
Targeted homozygous deletion of M-band titin in cardiomyocytes prevents sarcomere formation. J Cell Sci (2006) 1.18
Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis (2007) 1.18
Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res (2004) 1.18
Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg (2002) 1.17
Loss of the metalloprotease ADAM9 leads to cone-rod dystrophy in humans and retinal degeneration in mice. Am J Hum Genet (2009) 1.16
Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One (2010) 1.14
Proteomic analysis of fibrillin-rich microfibrils. Proteomics (2006) 1.13
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med (2006) 1.12
Reproducibility of first-pass cardiovascular magnetic resonance myocardial perfusion. J Magn Reson Imaging (2013) 1.11
Non-muscle myosins 2A and 2B drive changes in cell morphology that occur as myoblasts align and fuse. J Cell Sci (2006) 1.11
Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. Heart (2013) 1.08
Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol (2012) 1.06
Oestrogen receptors in the central nervous system and evidence for their role in the control of cardiovascular function. J Chem Neuroanat (2009) 1.06
Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res (2004) 1.06
Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair (2013) 1.05
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res (2013) 1.04
Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. J Am Coll Cardiol (2004) 1.03
Modulation of cell spreading and cell-substrate adhesion dynamics by dystroglycan. J Cell Sci (2010) 1.03
Dimerization of mammalian kinesin-3 motors results in superprocessive motion. Proc Natl Acad Sci U S A (2014) 1.03
Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis (2008) 1.02
Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res (2013) 1.01
The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol (2012) 1.01
Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes (2012) 1.01
Chronic beta2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc Res (2003) 1.00
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol (2007) 1.00